Effects of ALDH2 genotype, PPI treatment and L-cysteine on carcinogenic acetaldehyde in gastric juice and saliva after intragastric alcohol administration.
Level 3 - non-randomized controlled study
Non-randomized controlled physiological challenge study evaluating biochemical endpoints across genotype and treatment groups.
PubMed 25831092 · doi:10.1371/journal.pone.0120397
What was done
Researchers measured acetaldehyde concentrations in gastric juice and saliva following intragastric alcohol administration. The study evaluated the effects of ALDH2 genotype deficiency, proton pump inhibitor (PPI) treatment, low-dose ethanol exposure (analogous to fermented foods), and a slow-release L-cysteine capsule in ALDH2-active and ALDH2-deficient subjects.
What was found
The abstract reports no numerical values, effect estimates, or statistical significance metrics. Qualitatively, ALDH2 deficiency significantly increased gastric mucosa acetaldehyde exposure after alcohol administration. ALDH2 deficiency, PPI use, and L-cysteine caused independent changes in gastric juice and salivary acetaldehyde. Elevated acetaldehyde was also detected at low ethanol concentrations. A slow-release L-cysteine capsule eliminated acetaldehyde from the gastric juice in both ALDH2-active and ALDH2-deficient subjects receiving PPIs.
Why it matters
These findings suggest that gastric first-pass ethanol metabolism and PPI-induced microbial changes drive local acetaldehyde accumulation, providing a mechanistic link to gastric carcinogenesis and a candidate preventive role for L-cysteine.
Limits
The abstract provides no sample size (n), participant demographics, ethanol dosages, or quantitative measurements. Findings are limited to acute surrogate biochemical levels rather than cancer incidence or clinical endpoints.
Cited by
- supports Alcohol is classified as a Group 1 carcinogen by the World Health Organization.